Author Archives: admin


Stem Cell Clinic > Articles by: admin

Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

By Stem Cell Doctors

REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024, at 9:00 AM Eastern Time.

Read the rest here:
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference

By Stem Cell Doctors

NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that it will participate in Citi’s 2024 Global Healthcare Conference. Members of the Y-mAbs management team will host one-on-one meetings at the conference on Wednesday, December 4, 2024 in Miami, FL.

Read the original:
Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference

Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

By Stem Cell Doctors

WILMINGTON, Del., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens JMP Securities Hematology and Oncology Summit, taking place virtually on December 2, 2024.

Read the rest here:
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

Apyx Medical Corporation to Participate in the Piper Sandler 36th Annual Healthcare Conference

By Stem Cell Doctors

CLEARWATER, Fla., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that management will participate in the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024, in New York, NY.

Read the original post:
Apyx Medical Corporation to Participate in the Piper Sandler 36th Annual Healthcare Conference

Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates

By Stem Cell Doctors

WARRINGTON, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the third quarter ended September 30, 2024 and provided key business updates.

Follow this link:
Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates

Coherus Management to Participate in the 2024 Citi Global Healthcare Conference

By Stem Cell Doctors

REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in the 2024 Citi Global Healthcare Conference, with Dr. Theresa LaVallee, Chief Development Officer, sitting on the Novel Mechanisms in Oncology Panel on December 3, 2024, at 3:15 p.m. ET.

Read this article:
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference

PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area

By Stem Cell Doctors

Lyon (France) – November 27, 2024, at 02:30 p.m. CET – PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, presented an ambitious development strategy to take advantage of the rapidly evolving phage therapy area.

Go here to read the rest:
PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area

CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

By Stem Cell Doctors

SOUTH SAN FRANCISCO, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024, at 8:00 a.m. ET.

Continue reading here:
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

Recce Pharmaceuticals Granted Australia Patent for RECCE® Anti-Infectives

By Stem Cell Doctors

SYDNEY, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic anti-infectives, today announced the Australian Patent Office has formally granted Recce a family three patent for its anti-infectives, with expiry in 2037.

Read the original:
Recce Pharmaceuticals Granted Australia Patent for RECCE® Anti-Infectives

→←